3.68
-0.08(-2.13%)
Currency In USD
| Previous Close | 3.76 |
| Open | 3.71 |
| Day High | 3.73 |
| Day Low | 3.61 |
| 52-Week High | 6.19 |
| 52-Week Low | 1.66 |
| Volume | 111,720 |
| Average Volume | 452,294 |
| Market Cap | 222.77M |
| PE | -2.99 |
| EPS | -1.23 |
| Moving Average 50 Days | 4.7 |
| Moving Average 200 Days | 4.73 |
| Change | -0.08 |
If you invested $1000 in Rezolute, Inc. (RZLT) 10 years ago, it would be worth $36.98 as of March 13, 2025 at a share price of $3.68. Whereas If you bought $1000 worth of Rezolute, Inc. (RZLT) shares 5 years ago, it would be worth $817.78 as of March 13, 2025 at a share price of $3.68.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
GlobeNewswire Inc.
Feb 04, 2025 1:00 PM GMT
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses DMC approved enrollment of infants into the double-blind portion of
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
GlobeNewswire Inc.
Jan 31, 2025 1:00 PM GMT
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs,
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
GlobeNewswire Inc.
Jan 07, 2025 1:00 PM GMT
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in clinical development as a potential treatment for h